Ravulizumab

Common brands: Ultomiris, Soliris, Prednisone, Prednisone Delayed Release, Prednisone Tablets, Usp, 10 Mg

Top reporter: Alexion Pharmaceuticals Inc.

Complement Inhibitor [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Vitamin C [EPC]Provitamin D2 Compound [EPC]
12,242
Total Reports
11,009
Serious Reports
782
Death Reports
30
Reported Reactions
Death Report Ratio: High (6.39%)

Patient Demographics

Male
4,794
Female
5,648

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ravulizumab.

# Reaction Reports % of Total
1 FATIGUE 1,655
13.3%
2 ASTHENIA 824
6.6%
3 HEADACHE 712
5.7%
4 DRUG INEFFECTIVE 672
5.4%
5 OFF LABEL USE 531
4.3%
6 DYSPNOEA 470
3.8%
7 DEATH 469
3.8%
8 MUSCULAR WEAKNESS 468
3.8%
9 MYASTHENIA GRAVIS 428
3.4%
10 MALAISE 426
3.4%
11 HAEMOGLOBIN DECREASED 383
3.1%
12 PAIN 378
3.0%
13 BACK PAIN 352
2.8%
14 FEELING ABNORMAL 343
2.7%
15 DIPLOPIA 328
2.6%
16 DIARRHOEA 327
2.6%
17 THERAPEUTIC RESPONSE SHORTENED 326
2.6%
18 NAUSEA 312
2.5%
19 HAEMOLYSIS 302
2.4%
20 ARTHRALGIA 292
2.3%
21 DIZZINESS 266
2.1%
22 DYSPHAGIA 264
2.1%
23 GAIT DISTURBANCE 255
2.0%
24 EYELID PTOSIS 251
2.0%
25 COVID-19 250
2.0%
26 ILLNESS 249
2.0%
27 PYREXIA 237
1.9%
28 SYMPTOM RECURRENCE 236
1.9%
29 FALL 235
1.9%
30 NASOPHARYNGITIS 235
1.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.